Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04854434
Recruitment Status : Recruiting
First Posted : April 22, 2021
Last Update Posted : September 1, 2021
Sponsor:
Information provided by (Responsible Party):
Karyopharm Therapeutics Inc

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC). Approximately 78 participants with advanced or metastatic CRC will be enrolled, and randomized (1:1:1) into three arms A (selinexor only), B (selinexor and pembrolizumab), and C (standard of care [Combination of trifluridine and tipiracil]). Randomization will be based on stratification factors: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 versus 2. The end of treatment (EoT) visit will occur less than or equal to (<=30) days post-treatment discontinuation. A survival follow-up visit will be performed every 3 months from EoT and will continue for 12 months.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: Selinexor Drug: Pembrolizumab Drug: Trifluridine Drug: Tipiracil Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Actual Study Start Date : June 29, 2021
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A: Selinexor 80 mg
Participants will receive a single dose of 80 milligrams (mg) of selinexor once weekly (QW) (4 oral tablets of 20 mg each) on Day 1 of each week (days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) until progressive disease (PD), intolerable toxicity, or withdrawal from the study.
Drug: Selinexor
Participants will receive selinexor oral tablets.
Other Names:
  • Xpovio
  • KPT-330

Experimental: Arm B: Selinexor 80 mg and Pembrolizumab 400 mg
Participants will receive a single dose of 80 mg of selinexor tablets QW (4 oral tablets of 20 mg each) of selinexor oral tablets QW on Day 1 of each week (days 1, 8, 15, 22, 29, and 36) in combination with pembrolizumab 400 mg intravenously (IV) once every 6 weeks of each 42-day cycle until PD, intolerable toxicity, or withdrawal from the study.
Drug: Selinexor
Participants will receive selinexor oral tablets.
Other Names:
  • Xpovio
  • KPT-330

Drug: Pembrolizumab
Participants will receive pembrolizumab intravenously.
Other Name: Keytruda

Active Comparator: Arm C: Standard of care (SOC)
Participants will receive combination of trifluridine and tipiracil 35 milligrams per square meter (mg/m^2) per dose (15 mg tablet + 20 mg tablet) as oral tablets twice daily (BID) (maximum 80 mg allowed per dose) as SOC on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until PD, intolerable toxicity, or withdrawal from the study.
Drug: Trifluridine
Participants will receive trifluridine oral tablets as SOC.

Drug: Tipiracil
Participants will receive tipiracil oral tablets as SOC.




Primary Outcome Measures :
  1. Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for Arm B and C [ Time Frame: From the date of randomization until disease progression or death, whichever occurs first (up to 3 years) ]

Secondary Outcome Measures :
  1. Overall Survival (OS) for Arm A, B and C [ Time Frame: From the date of randomization up to death (up to 3 years) ]
  2. Overall Response Rate (ORR) Based on RECIST 1.1 for Arm A, B and C [ Time Frame: From the date of randomization up to death (up to 3 years) ]
  3. Progression-free Survival (PFS) at 6 Months for Arm A, B and C [ Time Frame: At 6 Months ]
  4. Percent Overall Survival (OS) in 6 Months for Arm A, B and C [ Time Frame: 6 Months ]
  5. Percent Overall Survival (OS) in 12 Months for Arm A, B and C [ Time Frame: 12 Months ]
  6. Duration of Response (DOR) Based on RECIST 1.1 for Arm A, B and C [ Time Frame: From the date of randomization until disease progression or death, whichever occurs first (up to 3 years) ]
  7. Disease Control Rate (DCR) Based on RECIST 1.1 for Arm A, B and C [ Time Frame: From the date of randomization up to death (up to 3 years) ]
  8. Progression-free Survival (PFS) Based on RECIST 1.1 for Arm A and C [ Time Frame: From the date of randomization until disease progression or death, whichever occurs first (up to 3 years ]
  9. Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity for Arm A, B and C [ Time Frame: From start of study drug administration up to follow-up (up to 3 years) ]
  10. Number of Participants With Clinical Significant Changes in Vital Signs, Clinical Laboratory Values, Electrocardiogram (ECG) and Physical Examination Findings for Arm A, B and C [ Time Frame: From start of study drug administration up to follow-up (up to 3 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants have histologically proven diagnosis of unresectable metastatic colorectal cancer with a known rat sarcoma (RAS) mutation.
  • Participants have measurable disease according to RECIST 1.1 criteria.
  • Have received 2-3 prior lines of systemic anticancer treatment (adjuvant or neoadjuvant therapy is not counted as one line of systemic therapy).
  • Participants with stable previously treated brain metastases are allowed.
  • ECOG performance status of 0-2 at the time of screening.
  • Age ≥ 18 years at the time of signing informed consent
  • Life expectancy of at least 3 months.
  • Female participants of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male participants must use an effective barrier method of contraception if sexually active throughout the study and for 4 months after the last dose of selinexor or pembrolizumab or 6 months after trifluridine and tipiracil.
  • Written informed consent signed in accordance with federal, local, and institutional guidelines.

Exclusion Criteria:

  • Prior treatment with a selective inhibitor of nuclear export (SINE) compound or selinexor.
  • Prior treatment with immune checkpoint inhibitors.
  • Participants with microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR).
  • Known allergy to any of study drugs (selinexor, pembrolizumab, and trifluridine and tipiracil) or the excipient of pembrolizumab.
  • Significant cardiovascular impairment, defined as:

    • Left ventricular ejection fraction ≤ 40 percent (%)
    • Active congestive heart failure (New York Heart Association [NYHA]) Class ≥ 3
    • Unstable angina or myocardial infarction within 3 months of enrollment
    • Serious and potentially life-threatening arrhythmia
  • Impaired hematopoietic function (any of the following would result in exclusion):

    • Absolute neutrophil count (ANC) less than (<) 1500/cubic millimeter (mm^3)
    • Platelet count < 100,000/ mm^3
    • Hemoglobin (Hb) < 10 gram per deciliter (g/dL)
  • Significant renal impairment, defined as: calculated creatinine clearance (CrCl) of < 30 milliliter per minute (mL/min) using the formula of Cockcroft and Gault.
  • Impaired hepatic function defined as: total bilirubin greater than (>) 1.5 × upper limit of normal (ULN) and aspartate transaminase (AST) > 2.5 x ULN, AST > 2.5 x ULN; for Arm B, unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin must be ≤ 4 x ULN.
  • Participants with a diagnosis of immunodeficiency or are receiving systemic steroid therapy (>10 mg/day of prednisone or equivalent) or any other form of immunosuppressive therapy. Participants with active autoimmune disease requiring systemic treatment during the past 2 years.

    • Participants with controlled type I and type II diabetes mellitus, and endocrinopathies such as hypothyroidism on stable hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are allowed.

Note: The Investigator needs to evaluate the participants medical history to confirm that they are eligible to receive the combination with pembrolizumab per these criteria.

  • Insufficient time since or not recovered from procedures or anti-cancer therapy, defined as:

    • Not recovered from major surgery ≤ 21 days prior to Day 1 dosing. Minor procedures, such as biopsies, dental work, or placement of a port or IV line for infusion are permitted.
    • Have ongoing clinically significant anti-cancer therapy-related toxicities Common Terminology Criteria for Adverse Events (CTCAE) Grade > 1. In specific cases, participants whose toxicity has stabilized or with Grade 2 non-hematologic toxicities can be allowed following documented approval by the Sponsor's Medical Monitor.
    • Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing.
    • Palliative radiotherapy > 14 days prior to the study is allowed.
    • Received investigational drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug (whichever is shorter), prior to Cycle 1 Day 1 (C1D1).
    • Live-attenuated vaccine against an infectious disease (e.g., nasal spray influenza vaccine) ≤ 14 days prior to the intended C1D1.
  • Female participants who are pregnant or lactating.
  • Active, ongoing or uncontrolled active infection requiring parenteral antibiotics, antivirals, antifungals within 1 week of Screening.
  • Participants with autoimmune disease, a medical condition that requires systemic corticosteroids or other immunosuppressive medication; or a history of interstitial lung disease.
  • Any gastrointestinal dysfunctions that could interfere with the absorption of selinexor (e.g. bowel obstruction, inability to swallow tablets, malabsorption syndrome, unresolved nausea, vomiting, diarrhea CTCAE > grade 1).
  • In the opinion of the investigator, participants who are below their ideal body weight and would be unduly impacted by changes in their weight.
  • Serious psychiatric or medical conditions that could interfere with participation in the study or in the opinion of the Investigator would make study involvement unreasonably hazardous.
  • Concurrent therapy with approved or investigational anticancer therapeutic including topical therapies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04854434


Contacts
Layout table for location contacts
Contact: Jatin Shah Chief Medical Officer, MD (617) 658-0600 jshah@karyopharm.com
Contact: Sharon Shacham Chief Scientific Officer, PhD (617) 658-0600 sshacham@karyopharm.com

Locations
Layout table for location information
United States, California
Valkyrie Clinical Trials Recruiting
Los Angeles, California, United States, 90067
Contact: Myo Zaw    626-632-1963    myo@alacritycare.com   
Principal Investigator: David Berz, MD, PhD, MPH         
United States, Florida
BRCR Global Recruiting
Plantation, Florida, United States, 33322
Contact: Valeria Moreno    561-447-0614    vmoreno@brcrglobal.com   
Principal Investigator: Harshad Amin, MD         
Sponsors and Collaborators
Karyopharm Therapeutics Inc
Layout table for additonal information
Responsible Party: Karyopharm Therapeutics Inc
ClinicalTrials.gov Identifier: NCT04854434    
Other Study ID Numbers: XPORT-CRC-041
First Posted: April 22, 2021    Key Record Dates
Last Update Posted: September 1, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Trifluridine
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents